Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Increasing participation in cervical cancer screening:Offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial

Tytuł :
Increasing participation in cervical cancer screening:Offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial
Autorzy :
Broberg, Gudrun
Gyrd-Hansen, Dorte
Jonasson, JM
Ryd, M-L
Holtenman, M
Miltom, I
Strander, Bjorn
Pokaż więcej
Temat :
HPV
cervical intraepithelial neoplasia
mass screening
non-attendance
papanicolaou smear
Self Care/economics
Telephone
Papanicolaou Test
Humans
Middle Aged
Vaginal Smears
Early Detection of Cancer/economics
Papillomavirus Infections/complications
Sweden
Uterine Cervical Neoplasms/diagnosis
Cost-Benefit Analysis
Adult
Female
Źródło :
Broberg, G, Gyrd-Hansen, D, Jonasson, JM, Ryd, M-L, Holtenman, M, Miltom, I & Strander, B 2014, ' Increasing participation in cervical cancer screening : Offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial ', International Journal of Cancer, vol. 134, no. 9, pp. 2223-2230 . https://doi.org/10.1002/ijc.28545
Rok publikacji :
2014
Kolekcja :
University_of_Southern_Denmark_Research_Output
Język :
English
ISSN :
0020-7136
2223-2230
DOI :
10.1002/ijc.28545
Numer akcesji :
edsair.od......3062..1a7b92ce37f01f04d41b10fa8945eb07
RACOMIP is a population-based, randomized trial of the effectiveness and cost-effectiveness of different interventions aimed at increasing participation in a well-run cervical cancer screening program in western Sweden. In this article, we report results from one intervention, offering non-attendees a high-risk human papillomavirus (HPV) self-test. Comparison was made with standard screening invitation routine or standard routine plus a telephone call. Women (8,800), aged 30-62, were randomly selected among women without a registered Pap smear in the two latest screening rounds. These women were randomized 1:5:5 to one of three arms: 800 were offered a high-risk HPV self-test, 4,000 were randomized to a telephone call (reported previously) and 4,000 constituted a control group (standard screening invitation routine). Results were based on intention to treat analysis and cost-effectiveness was calculated as marginal cost per cancer case prevented. The endpoint was the frequency of testing. The total response rate in the self-testing arm was 24.5%, significantly higher than in the telephone arm (18%, RR 1.36, 95% CI 1.19-1.57) and the control group (10.6%, RR 2.33, 95% CI 2.00-2.71). All nine women who tested positive for high-risk HPV attended for a cervical smear and colposcopy. From the health-care sector perspective, the intervention will most likely lead to no additional cost. Offering a self-test for HPV as an alternative to Pap smears increases participation among long-term non-attendees. Offering various screening options can be a successful method for increasing participation in this group.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies